Dialysis in the Treatment of Renal Failure


Dialysis may be required for the treatment of either acute or chronic kidney disease. The use of continuous renal replacement therapies (CRRT) and slow, low-efficiency dialysis (SLED) is specific to the management of acute renal failure and is discussed in Chap. 273. These modalities are performed continuously (CRRT) or over 6–12 hours per session (SLED), in contrast to the 3–4 hours of an intermittent hemodialysis session. Advantages and disadvantages of CRRT and SLED are discussed in Chap. 273.
Peritoneal dialysis is rarely used in developed countries for the treatment of acute renal failure because of the increased risk of infection and (as will be discussed in more detail below) less efficient clearance per unit of time. The focus of the majority of this chapter will be on the use of dialysis for end-stage renal disease (ESRD).
With the widespread availability of dialysis, the lives of hundreds of thousands of patients with ESRD have been prolonged. In the United States alone, there are now approximately 450,000 patients with ESRD, the vast majority of whom require dialysis. The incidence rate for ESRD is 330 cases per million population per year. The incidence of ESRD is disproportionately higher in African Americans (approximately 1000 per million population per year) as compared with white Americans (259 per million population per year). In the United States, the leading cause of ESRD is diabetes mellitus, currently accounting for nearly 45% of newly diagnosed cases of ESRD. Over one-quarter (27%) of patients have ESRD that has been attributed to hypertension, although it is unclear whether in these cases hypertension is the cause or a consequence of vascular disease or other unknown causes of kidney failure. Other important causes of ESRD include glomerulonephritis, polycystic kidney disease, and obstructive uropathy.
Globally, mortality rates for patients with ESRD are lowest in Europe and Japan but very high in the developing world because of the limited availability of dialysis. In the United States, the mortality rate of patients on dialysis is approximately 18–20% per year, with a 5-year survival rate of approximately 30–35%. Deaths are due mainly to cardiovascular diseases and infections (approximately 50 and 15% of deaths, respectively). Older age, male sex, nonblack race, diabetes mellitus, malnutrition, and underlying heart disease are important predictors of death.

 Treatment Options for ESRD Patients
Commonly accepted criteria for initiating patients on maintenance dialysis include the presence of uremic symptoms, the presence of hyperkalemia unresponsive to conservative measures, persistent extracellular volume expansion despite diuretic therapy, acidosis refractory to medical therapy, a bleeding diathesis, and a creatinine clearance or estimated glomerular filtration rate (GFR) below 10 mL/min per 1.73 m2 (see Chap. 274 for estimating equations). Timely referral to a nephrologist for advanced planning and creation of a dialysis access, education about ESRD treatment options, and management of the complications of advanced chronic kidney disease, including hypertension, anemia, acidosis, and secondary hyperparathyroidism, is advisable.
In ESRD, treatment options include hemodialysis (in center or at home); peritoneal dialysis, as either continuous ambulatory peritoneal dialysis (CAPD) or continuous cyclic peritoneal dialysis (CCPD); or transplantation (Chap. 276). Although there are geographic variations, hemodialysis remains the most common therapeutic modality for ESRD (>90% of patients) in the United States. In contrast to hemodialysis, peritoneal dialysis is continuous, but much less efficient, in terms of solute clearance. While no large-scale clinical trials have been completed comparing outcomes among patients randomized to either hemodialysis or peritoneal dialysis, outcomes associated with both therapies are similar in most reports, and the decision of which modality to select is often based on personal preferences and quality-of-life considerations.

Hemodialysis relies on the principles of solute diffusion across a semipermeable membrane. Movement of metabolic waste products takes place down a concentration gradient from the circulation into the dialysate. The rate of diffusive transport increases in response to several factors, including the magnitude of the concentration gradient, the membrane surface area, and the mass transfer coefficient of the membrane. The latter is a function of the porosity and thickness of the membrane, the size of the solute molecule, and the conditions of flow on the two sides of the membrane. According to the laws of diffusion, the larger the molecule, the slower its rate of transfer across the membrane. A small molecule, such as urea (60 Da), undergoes substantial clearance, whereas a larger molecule, such as creatinine (113 Da), is cleared less efficiently. In addition to diffusive clearance, movement of waste products from the circulation into the dialysate may occur as a result of ultrafiltration. Convective clearance occurs because of solvent drag, with solutes being swept along with water across the semipermeable dialysis membrane.

The Dialyzer
There are three essential components to hemodialysis: the dialyzer, the composition and delivery of the dialysate, and the blood delivery system (Fig. 275-1). The dialyzer consists of a plastic device with the facility to perfuse blood and dialysate compartments at very high flow rates. The surface area of modern dialysis membranes in adult patients is usually in the range of 1.5–2.0 m2. The hollow-fiber dialyzer is the most common in use in the United States. These dialyzers are composed of bundles of capillary tubes through which blood circulates while dialysate travels on the outside of the fiber bundle. 

Figure 275-1
Schema for hemodialysis.

Recent advances have led to the development of many different types of membrane material. Broadly, there are four categories of dialysis membranes: cellulose, substituted cellulose, cellulosynthetic, and synthetic. Over the past three decades, there has been a gradual switch from cellulose-derived to synthetic membranes, because the latter are more "biocompatible." Bioincompatibility is generally defined as the ability of the membrane to activate the complement cascade.
Cellulosic membranes are bioincompatible because of the presence of free hydroxyl groups on the membrane surface. In contrast, with the substituted cellulose membranes (e.g., cellulose acetate) or the cellulosynthetic membranes, the hydroxyl groups are chemically bound to either acetate or tertiary amino groups, resulting in limited complement activation. Synthetic membranes, such as polysulfone, polymethylmethacrylate, and polyacrylonitrile membranes, are even more biocompatible because of the absence of these hydroxyl groups. Polysulfone membranes are now used in minus 60% of the dialysis treatments in the United States.
Reprocessing and reuse of hemodialyzers are often employed for patients on maintenance hemodialysis in the United States. However, as the manufacturing costs for disposable dialyzers have declined, more and more outpatient dialysis facilities are no longer reprocessing dialyzers. In most centers employing reuse, only the dialyzer unit is reprocessed and reused, whereas in the developing world blood lines are also frequently reused. The reprocessing procedure can be either manual or automated. It consists of the sequential rinsing of the blood and dialysate compartments with water, a chemical cleansing step with reverse ultrafiltration from the dialysate to the blood compartment, the testing of the patency of the dialyzer, and, finally, disinfection of the dialyzer. Formaldehyde, peracetic acid–hydrogen peroxide, glutaraldehyde, and bleach have all been used as reprocessing agents.

The potassium concentration of dialysate may be varied from 0 to 4 mmol/L depending on the predialysis plasma potassium concentration. The usual dialysate calcium concentration in U.S. hemodialysis centers is 1.25 mmol/L (2.5 meq/L), although modification may be required in selected settings (e.g., higher dialysate calcium concentrations may be used in patients with hypocalcemia associated with secondary hyperparathyroidism or following parathyroidectomy). The usual dialysate sodium concentration is 140 mmol/L. Lower dialysate sodium concentrations are associated with a higher frequency of hypotension, cramping, nausea, vomiting, fatigue, and dizziness. In patients who frequently develop hypotension during their dialysis run, "sodium modeling" to counterbalance urea-related osmolar gradients is often used. When sodium modeling, the dialysate sodium concentration is gradually lowered from the range of 145–155 meq/L to isotonic concentrations (140 meq/L) near the end of the dialysis treatment, typically declining either in steps or in a linear or exponential fashion. Because patients are exposed to approximately 120 L of water during each dialysis treatment, water used for the dialysate is subjected to filtration, softening, deionization, and, ultimately, reverse osmosis. During the reverse osmosis process, water is forced through a semipermeable membrane at very high pressure to remove microbiologic contaminants and  less than 90% of dissolved ions.

Blood Delivery System
The blood delivery system is composed of the extracorporeal circuit in the dialysis machine and the dialysis access. The dialysis machine consists of a blood pump, dialysis solution delivery system, and various safety monitors. The blood pump moves blood from the access site, through the dialyzer, and back to the patient. The blood flow rate may range from 250–500 mL/min, depending largely on the type and integrity of the vascular access. Negative hydrostatic pressure on the dialysate side can be manipulated to achieve desirable fluid removal or ultrafiltration. Dialysis membranes have different ultrafiltration coefficients (i.e., mL removed/min per mmHg) so that along with hydrostatic changes, fluid removal can be varied. The dialysis solution delivery system dilutes the concentrated dialysate with water and monitors the temperature, conductivity, and flow of dialysate.

Dialysis Access
The fistula, graft, or catheter through which blood is obtained for hemodialysis is often referred to as a dialysis access. A native fistula created by the anastomosis of an artery to a vein (e.g., the Brescia-Cimino fistula, in which the cephalic vein is anastomosed end-to-side to the radial artery) results in arterialization of the vein. This facilitates its subsequent use in the placement of large needles (typically 15 gauge) to access the circulation. Although fistulas have the highest long-term patency rate of all dialysis access options, fistulas are created in a minority of patients in the United States. Many patients undergo placement of an arteriovenous graft (i.e., the interposition of prosthetic material, usually polytetrafluoroethylene, between an artery and a vein) or a tunneled dialysis catheter. In recent years, nephrologists, vascular surgeons, and health care policy makers in the United States have encouraged creation of arteriovenous fistulas in a larger fraction of patients (the "fistula first" initiative). Unfortunately, even when created, arteriovenous fistulas may not mature sufficiently to provide reliable access to the circulation, or they may thrombose early in their development. Novel surgical approaches (e.g., brachiobasilic fistula creation with transposition of the basilic vein fistula to the arm surface) have increased options for "native" vascular access.
Grafts and catheters tend to be used among persons with smaller-caliber veins or persons whose veins have been damaged by repeated venipuncture, or after prolonged hospitalization. The most important complication of arteriovenous grafts is thrombosis of the graft and graft failure, due principally to intimal hyperplasia at the anastomosis between the graft and recipient vein. When grafts (or fistulas) fail, catheter-guided angioplasty can be used to dilate stenoses; monitoring of venous pressures on dialysis and of access flow, though not routinely performed, may assist in the early recognition of impending vascular access failure. In addition to an increased rate of access failure, grafts and (in particular) catheters are associated with much higher rates of infection than fistulas.
Intravenous large-bore catheters are often used in patients with acute and chronic kidney disease. For persons on maintenance hemodialysis, tunneled catheters (either two separate catheters or a single catheter with two lumens) are often used when arteriovenous fistulas and grafts have failed or are not feasible due to anatomical considerations. These catheters are tunneled under the skin; the tunnel reduces bacterial translocation from the skin, resulting in a lower infection rate than with nontunneled temporary catheters. Most tunneled catheters are placed in the internal jugular veins; the external jugular, femoral, and subclavian veins may also be used. Nephrologists, interventional radiologists, and vascular surgeons generally prefer to avoid placement of catheters into the subclavian veins; while flow rates are usually excellent, subclavian stenosis is a frequent complication and, if present, will likely prohibit permanent vascular access (i.e., a fistula or graft) in the ipsilateral extremity. Infection rates may be higher with femoral catheters. For patients with multiple vascular access complications and no other options for permanent vascular access, tunneled catheters may be the last "lifeline" for hemodialysis. Translumbar or transhepatic approaches into the inferior vena cava may be required if the superior vena cava or other central veins draining the upper extremities are stenosed or thrombosed.

Goals of Dialysis
The hemodialysis procedure is targeted at removing both low- and high-molecular-weight solutes. The procedure consists of pumping heparinized blood through the dialyzer at a flow rate of 300–500 mL/min, while dialysate flows in an opposite counter-current direction at 500–800 mL/min. The efficiency of dialysis is determined by blood and dialysate flow through the dialyzer as well as dialyzer characteristics (i.e., its efficiency in removing solute). The dose of dialysis, which is currently defined as a derivation of the fractional urea clearance during a single dialysis treatment, is further governed by patient size, residual kidney function, dietary protein intake, the degree of anabolism or catabolism, and the presence of comorbid conditions.
Since the landmark studies of Sargent and Gotch relating the measurement of the dose of dialysis using urea concentrations with morbidity in the National Cooperative Dialysis Study, the delivered dose of dialysis has been measured and considered as a quality assurance and improvement tool. While the fractional removal of urea nitrogen and derivations thereof are considered to be the standard methods by which "adequacy of dialysis" is measured, a large multicenter randomized clinical trial (the HEMO Study) failed to show a difference in mortality associated with a large difference in urea clearance. Still, multiple observational studies and widespread expert opinion have suggested that higher dialysis dose is warranted; current targets include a urea reduction ratio (the fractional reduction in blood urea nitrogen per hemodialysis session) of more than 65–70% and a body water–indexed clearance x time product (KT/V) above 1.3 or 1.05, depending on whether urea concentrations are "equilibrated."
For the majority of patients with ESRD, between 9 and 12 h of dialysis are required each week, usually divided into three equal sessions. Several studies have suggested that longer hemodialysis session lengths may be beneficial, although these studies are confounded by a variety of patient characteristics, including body size and nutritional status. Hemodialysis "dose" should be individualized, and factors other than the urea nitrogen should be considered, including the adequacy of ultrafiltration or fluid removal. Several authors have highlighted improved intermediate outcomes associated with more frequent hemodialysis (i.e., more than three times a week), although these studies are also confounded by multiple factors. A randomized clinical trial is currently underway to test whether more frequent dialysis results in differences in a variety of physiologic and functional markers.

Complications during Hemodialysis
Hypotension is the most common acute complication of hemodialysis, particularly among diabetics. Numerous factors appear to increase the risk of hypotension, including excessive ultrafiltration with inadequate compensatory vascular filling, impaired vasoactive or autonomic responses, osmolar shifts, overzealous use of antihypertensive agents, and reduced cardiac reserve. Patients with arteriovenous fistulas and grafts may develop high output cardiac failure due to shunting of blood through the dialysis access; on rare occasions, this may necessitate ligation of the fistula or graft. Because of the vasodilatory and cardiodepressive effects of acetate, its use as the buffer in dialysate was once a common cause of hypotension. Since the introduction of bicarbonate-containing dialysate, dialysis-associated hypotension has become less common. The management of hypotension during dialysis consists of discontinuing ultrafiltration, the administration of 100–250 mL of isotonic saline or 10 mL of 23% saturated hypertonic saline, and administration of salt-poor albumin. Hypotension during dialysis can frequently be prevented by careful evaluation of the dry weight and by ultrafiltration modeling, such that more fluid is removed at the beginning rather than the end of the dialysis procedure. Additional maneuvers include the performance of sequential ultrafiltration followed by dialysis; the use of midodrine, a selective 1-adrenergic pressor agent; cooling of the dialysate during dialysis treatment; and avoiding heavy meals during dialysis.
Muscle cramps during dialysis are also a common complication of the procedure. The etiology of dialysis-associated cramps remains obscure. Changes in muscle perfusion because of excessively aggressive volume removal, particularly below the estimated dry weight, and the use of low-sodium–containing dialysate, have been proposed as precipitants of dialysis-associated cramps. Strategies that may be used to prevent cramps include reducing volume removal during dialysis, ultrafiltration profiling, and the use of higher concentrations of sodium in the dialysate or sodium modeling (see above).
Anaphylactoid reactions to the dialyzer, particularly on its first use, have been reported most frequently with the bioincompatible cellulosic-containing membranes. With the gradual phasing out of cuprophane membranes in the United States, dialyzer reactions have become relatively uncommon. Dialyzer reactions can be divided into two types, A and B. Type A reactions are attributed to an IgE-mediated intermediate hypersensitivity reaction to ethylene oxide used in the sterilization of new dialyzers. This reaction typically occurs soon after the initiation of a treatment (within the first few minutes) and can progress to full-blown anaphylaxis if the therapy is not promptly discontinued. Treatment with steroids or epinephrine may be needed if symptoms are severe. The type B reaction consists of a symptom complex of nonspecific chest and back pain, which appears to result from complement activation and cytokine release. These symptoms typically occur several minutes into the dialysis run and typically resolve over time with continued dialysis.
Cardiovascular diseases constitute the major causes of death in patients with ESRD. Cardiovascular mortality and event rates are higher in dialysis patients than in patients posttransplantation, although rates are extraordinarily high in both populations. The underlying cause of cardiovascular disease is unclear but may be related to shared risk factors (e.g., diabetes mellitus), chronic inflammation, massive changes in extracellular volume (especially with high interdialytic weight gains), inadequate treatment of hypertension, dyslipidemia, anemia, dystrophic vascular calcification, hyperhomocysteinemia, and, perhaps, alterations in cardiovascular dynamics during the dialysis treatment. Few studies have targeted cardiovascular risk reduction in ESRD patients; none have demonstrated consistent benefit. Nevertheless, most experts recommend conventional cardioprotective strategies (e.g., lipid-lowering agents, aspirin, -adrenergic antagonists) in dialysis patients based on the patients' cardiovascular risk profile, which appears to be increased by more than an order of magnitude relative to persons unaffected by kidney disease.

Peritoneal Dialysis
In peritoneal dialysis, 1.5–3 L of a dextrose-containing solution is infused into the peritoneal cavity and allowed to dwell for a set period of time, usually 2–4 h. As with hemodialysis, toxic materials are removed through a combination of convective clearance generated through ultrafiltration and diffusive clearance down a concentration gradient. The clearance of solutes and water during a peritoneal dialysis exchange depends on the balance between the movement of solute and water into the peritoneal cavity versus absorption from the peritoneal cavity. The rate of diffusion diminishes with time and eventually stops when equilibration between plasma and dialysate is reached. Absorption of solutes and water from the peritoneal cavity occurs across the peritoneal membrane into the peritoneal capillary circulation and via peritoneal lymphatics into the lymphatic circulation. The rate of peritoneal solute transport varies from patient to patient and may be altered by the presence of infection (peritonitis), drugs, and physical factors such as position and exercise.

Forms of Peritoneal Dialysis
Peritoneal dialysis may be carried out as continuous ambulatory peritoneal dialysis (CAPD), continuous cyclic peritoneal dialysis (CCPD), or a combination of both. In CAPD, dialysis solution is manually infused into the peritoneal cavity during the day and exchanged three to five times daily. A nighttime dwell is frequently instilled at bedtime and remains in the peritoneal cavity through the night. The drainage of spent dialysate is performed manually with the assistance of gravity to move fluid out of the abdomen. In CCPD, exchanges are performed in an automated fashion, usually at night; the patient is connected to an automated cycler that performs a series of exchange cycles while the patient sleeps. The number of exchange cycles required to optimize peritoneal solute clearance varies by the peritoneal membrane characteristics; as with hemodialysis, experts suggest careful tracking of solute clearances to ensure dialysis "adequacy."
Peritoneal dialysis solutions are available in volumes typically ranging from 1.5 to 3.0 L. Lactate is the preferred buffer in peritoneal dialysis solutions. The most common additives to peritoneal dialysis solutions are heparin to prevent obstruction of the dialysis catheter lumen with fibrin and antibiotics during an episode of acute peritonitis. Insulin may also be added in patients with diabetes mellitus.

Access to the Peritoneal Cavity
Access to the peritoneal cavity is obtained through a peritoneal catheter. Catheters used for maintenance peritoneal dialysis are flexible, being made of silicon rubber with numerous side holes at the distal end. These catheters usually have two Dacron cuffs to promote fibroblast proliferation, granulation, and invasion of the cuff. The scarring that occurs around the cuffs anchors the catheter and seals it from bacteria tracking from the skin surface into the peritoneal cavity; it also prevents the external leakage of fluid from the peritoneal cavity. The cuffs are placed in the preperitoneal plane and ~2 cm from the skin surface.
The peritoneal equilibrium test is a formal evaluation of peritoneal membrane characteristics that measures the transfer rates of creatinine and glucose across the peritoneal membrane. Patients are classified as low, low–average, high–average, and high "transporters." Patients with rapid equilibration (i.e., high transporters) tend to absorb more glucose and lose efficiency of ultrafiltration with long daytime dwells. High transporters also tend to lose larger quantities of albumin and other proteins across the peritoneal membrane. In general, patients with rapid transporting characteristics require more frequent, shorter dwell time exchanges, nearly always obligating use of a cycler for feasibility. Slower (low and low–average) transporters tend to do well with fewer exchanges. The efficiency of solute clearance also depends on the volume of dialysate infused. Larger volumes allow for greater solute clearance, particularly with CAPD in patients with low and low–average transport characteristics. Interestingly, solute clearance also increases with physical activity, presumably related to more efficient flow dynamics within the peritoneal cavity.
As with hemodialysis, the optimal dose of peritoneal dialysis is unknown. Several observational studies have suggested that higher rates of urea and creatinine clearance (the latter generally measured in L/week) are associated with lower mortality rates and fewer uremic complications. However, a randomized clinical trial (ADEMEX) failed to show a significant reduction in mortality or complications with a relatively large increment in urea clearance. In general, patients on peritoneal dialysis do well when they retain residual kidney function. The rates of technique failure increase with years on dialysis and have been correlated with loss of residual function to a greater extent than loss of peritoneal membrane capacity. Recently, a nonabsorbable carbohydrate (icodextrin) has been introduced as an alternative osmotic agent. Studies have demonstrated more efficient ultrafiltration with icodextrin than with dextrose-containing solutions. Icodextrin is typically used as the "last fill" for patients on CCPD or for the longest dwell in patients on CAPD. For some patients in whom CCPD does not provide sufficient solute clearance, a hybrid approach can be adopted where one or more daytime exchanges are added to the CCPD regimen. While this approach can enhance solute clearance and prolong a patient's capacity to remain on peritoneal dialysis, the burden of the hybrid approach can be overwhelming to some.

Complications during Peritoneal Dialysis
The major complications of peritoneal dialysis are peritonitis, catheter-associated nonperitonitis infections, weight gain and other metabolic disturbances, and residual uremia (especially among patients with no residual kidney function).
Peritonitis typically develops when there has been a break in sterile technique during one or more of the exchange procedures. Peritonitis is usually defined by an elevated peritoneal fluid leukocyte count (100/mm3, of which at least 50% are polymorphonuclear neutrophils). The clinical presentation typically consists of pain and cloudy dialysate, often with fever and other constitutional symptoms. The most common culprit organisms are gram-positive cocci, including Staphylococcus, reflecting the origin from the skin. Gram-negative rod infections are less common; fungal and mycobacterial infections can be seen in selected patients, particularly after antibacterial therapy. Most cases of peritonitis can be managed either with intraperitoneal or oral antibiotics, depending on the organism; many patients with peritonitis do not require hospitalization. In cases where peritonitis is due to hydrophilic gram negative rods (e.g., Pseudomonas sp.) or yeast, antimicrobial therapy is usually not sufficient, and catheter removal is required to ensure complete eradication of infection. Nonperitonitis catheter-associated infections (often termed tunnel infections) vary widely in severity. Some cases can be managed with local antibiotic or silver nitrate administration, while others are severe enough to require parenteral antibiotic therapy and catheter removal.
Peritoneal dialysis is associated with a variety of metabolic complications. As noted above, albumin and other proteins can be lost across the peritoneal membrane in concert with the loss of metabolic wastes. The hypoproteinemia induced by peritoneal dialysis obligates a higher dietary protein intake in order to maintain nitrogen balance. Hyperglycemia and weight gain are also common complications of peritoneal dialysis. Several hundred calories in the form of dextrose are absorbed each day, depending on the concentration employed. Peritoneal dialysis patients, particularly those with type II diabetes mellitus, are then prone to other complications of insulin resistance, including hypertriglyceridemia. On the positive side, the continuous nature of peritoneal dialysis usually allows for a more liberal diet, due to continuous removal of potassium and phosphorus—two major dietary components whose accumulation can be hazardous in ESRD.

Global Perspective
The incidence of ESRD is increasing worldwide with longer life expectancies and improved care of infectious and cardiovascular diseases. The management of ESRD varies widely by country and within country by region, and it is influenced by economic and other major factors. In general, peritoneal dialysis is more commonly performed in poorer countries owing to its lower expense and the high cost of establishing in-center hemodialysis units.

Further Readings
  1. Burkart JM et al: Peritoneal dialysis, in Brenner and Rector's The Kidney, 7th ed, BM Brenner (ed). Philadelphia, Saunders, 2004
  2. Eknoyan G et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 346:2010, 2002
  3. Forni LG, Hilton PJ: Current concepts: Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med 336:1303, 1997 [PMID: 9113935]
  4. Himmelfarb J, Kliger AS: End-stage renal disease measures of quality. Annu Rev Med 58:387, 2007 [PMID: 17217331]
  5. National Kidney Foundation: Kidney Disease Quality Initiative Clinical Practice Guidelines: Hemodialysis and peritoneal dialysis adequacy, 2001. Available online at http://www.kidney.org/professionals/ kdoqi/guidelines.cfm
  6. Paniagua R et al: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13:1307, 2002 [PMID: 11961019]
  7. Rayner HC et al: Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): Performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis. 44:S22, 2004
  8. U.S. Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2005
Suplement pelangsing terbaik. Lulus Standard GMP (Good Manufacturing Practice) dan uji tes SGS. Pesan sekarang Juga!!!
(Jamu Tetes)Mengatasi diabetes, hypertensi, kanker payudara, mengurangi resiko stroke, meningkatkan fungsi otak, dll.
Theraskin Acne Mask (Masker bentuk pasta untuk kulit berjerawat). Untuk membantu mengeringkan jerawat.
Melindungi kulit terhadap efek buruk sinar matahari, menjadikan kulit tampak lenih cerah dan menyamarkan noda hitam di wajah.
Khusus dari tanaman obat pilihan untuk penderita kencing manis (Diabetes) sehingga dapat membantu menstabilkan gula darah

ADVERTISE HERE Ads by Sikkahoder
Body Whitening
Mengandung vit C+E, AHA, Pelembab, SPF 30, Fragrance, n Solk Protein yang memutihkan kulit secara bertahap dan PERMANEN!!
Dengan alat ini, tidak perlu lg memencet hidung, atau bagian wajah lainnya untuk mengeluarkan komedo.
Obat Keputihan
Crystal-X adalah produk dari bahan-bahan alami yang mengandung Sulfur, Antiseptik, Minyak Vinieill. Membersihkan alat reproduksi wanita hingga kedalam.
Obat herbal yang diramu khusus bagi penderita Wasir (Ambeien), juga bermanfaat untuk melancarkan buang air besar dan mengurangi peradangan pada pembuluh darah anus
Termometer digital dengan suara Beep. Mudah digunakan, gampang dibaca dengan display LCD dan suara beep ketika selesai mendeteksi suhu.

ADVERTISE HERE Ads by Sikkahoder